Directly Compressible Granules

  • Directly Compressible Granules 1
  • Directly Compressible Granules 2
  • Directly Compressible Granules 3
Product Description

1. Aceclofenac Granules 50%2. Clopidogrel Granules 60%
3. Fexofenadine Granules 48%
4. Gliclazide Granules SR 48%
5. Levitiracetam Granules SR 75%, 80%
6. Lisinopril Granules 50%
7. Metformin HCL Granules IR 86.66%, 93%
8. Metformin HCL Granules SR 75%, 80%
9. Montelukast Granules 7.1%
10. Paracetamol Granules 83%, 90%, 96%
11. Sildenafil Citrate Granules 25%
12. Sitagliptin Granules 25.3%
13. Tadalafil Granules 20%
14. Telmisartan Granules 20%
15. Valproic acid Granules SR 66.7%
16. Vildagliptin Granules 25.3%

Read more Show less

YSK Laboratories Pvt Ltd

  • IN
  • 2023
    On CPHI since
  • 1 - 24
    Employees
Company types
Manufacturer/Innovator
Primary activities
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Anti-Allergens; Bone & Joint Health; Brand Name; Cardiovascular Health; Children's Health F&B; Cognitive & Mental Function; Convenience; Digestive Health; Energy & Endurance; Ethical Sourcing; Experienced Technicians; Green Product; Guarantee/Warranty; Halal Ingredients; Immune Health; International Approvals/Standards; Kosher Ingredients; Natural Ingredients; Packaging; Place of Origin; Price; Product Features; Product Performance; Prompt Delivery; Quality Service; Reputation; Salt, Fat, Sugar Reduction; Small Orders Accepted; Sustainability; Weight Loss Management; 1. State of the art manufacturing facility.
    2. Designed to comply with WHO, MHRA, USFDA, EUGMP, TGA and all other regulatory authorities 


    3. Upto 500MT of DC Granules production annually 


    4. Experienced team of personnel 


    5. Continuous product development 


    6. Improved solubility 


    7. Better dissolution profiles


    8. Miniaturisation of tablet size 


    9. Reduction in Exipient load 


    10. In-process testing eliminated 


    11. Processing time and costs reduced 


    12. Cost effectiveness 


    13. Higher production efficiencies and freeing up of plant capacities 


    14. Free of Organic Volatile impurities 
  • Model
    DC Granules
  • Supplied from
    India
More specifications Fewer specifications
Sales Markets
Show more Show less

YSK Laboratories Pvt Ltd

  • IN
  • 2023
    On CPHI since
  • 1 - 24
    Employees
Company types
Manufacturer/Innovator
Primary activities
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

More Products from YSK Laboratories Pvt Ltd (2)

  • Directly Compressible (DC) Granules Product List

    Product Directly Compressible (DC) Granules Product List

    Aceclofenac Granules = 48% Amlodipine Granules = 66.70% Clopidogrel Granules = 48% Fexofenadine Granules = 25.30% Gliclazide SR Granules = 25.30% Levetiracetam SR Granules = 7.10% Lisinopril Granules = 12.5%, 16% Montelukast Granules = 50% Paracetamol Granules = 83%, 90%, 96% Sildenafil Citrate Granules = ...
  • Metformin DC Granules

    Product Metformin DC Granules

    Immediate Release = 86.66% and 95% Sustained Release = 75% and 80%

YSK Laboratories Pvt Ltd resources (2)

  • YSK Labs - CCD partners Watchlist 2023

    News YSK Labs - CCD partners Watchlist 2023

    YSK Labs was featured on the CCD partners Watchlist 2023 aimed to highlight the profile of Innovative and disruptive Startup companies participating in the CPHI Startup Market 2023. This Watchlist is designed to capture and track exciting up-and-coming businesses with the potential to disrupt the pharmaceutical industry. 

    Out of approximately 1000+ companies in over 57 countries, YSK Labs was amongst the 21 companies selected and featured. 
    14 Sep 2023
  • YSK Brochure 1

    Brochure YSK Brochure 1